Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile Group LLC as well as new investors Fidelity Management & Research Company LLC, and funds and accounts advised by T. Rowe Price Associates, Inc.
Saluda Medical advises the net proceeds from the financing will be used to operationalize and scale commercialization of the Evoke® Spinal Cord Simulation System (SCS) for chronic pain and to further advance the Company’s technology platform across an emerging portfolio of transformational neuromodulation therapies.
Evoke® is the only spinal cord stimulation technology designed to measure the spinal cord’s response to stimulation and make automatic, real-time adjustments intended to maintain a consistent level of pain therapy.
“We are thrilled to partner with this group of leading healthcare investors who share our vision of elevating the standard of care in neuromodulation fields with large unmet patient needs,” said Jim Schuermann, President and CEO of Saluda Medical. “The full impact of our innovation can only be realized by enabling more patients to be treated with our evidence-based technologies designed to improve long-term outcomes while reducing the burden of care, and we wish to thank our new and existing investors for their partnership in our journey to achieve this mission.”
Saluda Medical has pioneered innovations designed to read, record, and respond to nerves during stimulation and over the last decade has advanced the technology to enable dosing that can be titrated at the microsecond level to maintain and optimize consistent therapy for patients. The Company executed the first double-blind pivotal randomized controlled trial (RCT) in the history of spinal cord stimulation (SCS) that showed nearly 9 out 10 patients experience long-term pain relief and clinically meaningful improvements in quality of life, performing activities of daily living, sleep, mood and opioid reduction with zero explants due to loss of efficacy. Evoke is the only spinal cord stimulation therapy to have the pivotal study results published in premier clinical neurology journals The Lancet Neurology and JAMA Neurology.
Chronic pain affects more than 540 million people globally. Although spinal cord stimulation has been used as a treatment option for chronic pain since 1967, Evoke is the first system designed to automatically self-adjust with microsecond precision to optimize therapy based on a patient’s unique spinal cord activity.
